- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest, NXP900 / Nuvectis Pharma
Journal: Corneal Edema in Inducible Slc4a11 Knockout Is Initiated by Mitochondrial Superoxide Induced Src Kinase Activation. (Pubmed Central) - Jun 14, 2023
Mitochondrial uncouplers may be exploited as possible therapeutic candidates to treat excessive inflammation in endothelium, by changing the methylation status of genomic DNA. Slc4a11 KO-induced CE oxidative stress triggered increased Src kinase activity that resulted in perturbation of the pump components and barrier function of the CE.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Penetration of Triphenylphosphonium Derivatives through the Cell Envelope of Bacteria of Mycobacteriales Order. (Pubmed Central) - May 27, 2023
Mitochondria-targeted antioxidant and antibiotic SkQ1 (10-(plastoquinonyl)decyltriphenylphosphonium) is an excellent model for studying the penetration of substances through the bacterial cell envelope...One, but probably not the only such mechanism is a decrease in membrane potential, which is important for the implementation of many cellular processes. Thus, neither the presence of MDR pumps, nor the presence of porins, prevents the penetration of SkQ1 and CTPP through the complex cell envelope of R. fascians and M. tuberculosis.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Mitochondrial antioxidant SkQ1 decreases inflammation following hemorrhagic shock by protecting myocardial mitochondria. (Pubmed Central) - Dec 6, 2022
HS causes damage to the rat myocardial mitochondrial structure, increases mtDNA release and ROS contents, activates the mitochondrial and ROS-related pathways, and induces systemic inflammatory response. The mitochondrial antioxidant SkQ1 can improve rat myocardial mitochondria ultrastructure, reduce mtDNA and ROS contents, and decrease inflammation by protecting myocardial mitochondria, thereby playing a novel protective role in HS.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Mitochondrial Targeted Antioxidant SKQ1 Ameliorates Acute Kidney Injury by Inhibiting Ferroptosis. (Pubmed Central) - Oct 11, 2022
Our results revealed that SKQ1 treatment greatly reversed renal outcomes in cisplatin, ischemia-reperfusion injury (IRI), or folic acid-induced AKI models...In conclusion, SKQ1 treatment protected against ischemic- or nephrotoxic-induced AKI by inhibiting ferroptosis in vivo and in vitro. These results could facilitate a broader understanding of the interaction between mitochondrial antioxidants and ferroptotic defense mechanisms, providing a possible therapeutic strategy in AKI.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Mitochondrial Antioxidant SkQ1 Has a Beneficial Effect in Experimental Diabetes as Based on the Analysis of Expression of microRNAs and mRNAs for the Oxidative Metabolism Regulators. (Pubmed Central) - Nov 29, 2021
Rats with experimental diabetes induced by the intraperitoneal injection of alloxan were subjected to the antioxidant pre-therapy with a series of mitochondria-targeted 10-(6'-plastoquinonyl)decyltriphenylphosphonium (SkQ1) injections and analyzed for the expression of mRNAs and microRNAs by real-time quantitative polymerase chain reaction to identify potential predictors of diabetes...Mitochondria-targeted antioxidant SkQ1 demonstrates positive effects on several levels, from the normalization of the blood glucose content to genetic and epigenetic changes. Our results can serve as a basis for the development of novel therapeutic and diagnostic strategies.
- |||||||||| ABP-300 / Abpro Therap, BIO invest, Mabwell (Shanghai) Biosci
Clinical, P1 data, PK/PD data, Journal: Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: A Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody. (Pubmed Central) - Sep 1, 2021
P1, P2, P2
The positive rates of serum ADAs and antibody titers were low with no evidence of an impact on safety or PK. In conclusion, MW33 was well-tolerated, demonstrated linear PK, with a lower positive rate of serum ADAs and antibody titers in healthy subjects.Trial registration: ClinicalTrials.gov identifier: NCT04427501..Trial registration: ClinicalTrials.gov identifier: NCT04533048..Trial registration: ClinicalTrials.gov identifier: NCT04627584..
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Preclinical, Journal: MEK1/2-ERK Pathway Alterations as a Therapeutic Target in Sporadic Alzheimer's Disease: A Study in Senescence-Accelerated OXYS Rats. (Pubmed Central) - Jul 4, 2021
Previously, using senescence-accelerated OXYS rats, which simulate key characteristics of the sporadic AD type, we have shown that prolonged treatment with mitochondria-targeted antioxidant plastoquinonyl-decyltriphenylphosphonium (SkQ1) during active progression of AD-like pathology improves the activity of many signaling pathways (SPs) including the p38 MAPK SP...SkQ1 decreased hyperphosphorylation of tau protein, which is present in pathological aggregates in AD. Thus, SkQ1 alleviates AD pathology by suppressing MEK1/2-ERK1/2 SP activity in the OXYS rat hippocampus and may be a promising candidate drug for human AD.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Autophagy as a Target for the Retinoprotective Effects of the Mitochondria-Targeted Antioxidant SkQ1. (Pubmed Central) - Jun 26, 2021
The treatment with SkQ1 (250 nmol/kg body weight) during the period of active disease progression (from 12 to 18 months of age) completely prevented progression of clinical manifestations of retinopathy in the OXYS rats, suppressed atrophic changes in the RPE cells and activated autophagy in the retina, which was evidenced by a significant decrease in the content of the multifunctional adapter protein p62/Sqstm1 and increase in the level of the Beclin1 gene mRNA. In general, the results obtained earlier and in the present study have shown that SkQ1 is a promising agent for prevention and suppression of AMD.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Preclinical, Journal: Anthelmintic Activity of Antioxidants: In Vitro Effects on the Liver Fluke Opisthorchis felineus. (Pubmed Central) - Apr 7, 2021
Results of our study indicate that SkQ1 and flavonoids have high anthelmintic activities against the liver flukes. We propose that structure-activity relationship research might be worthwhile based on the structures of the most effective substances.
- |||||||||| ABP-300 / Abpro Therap, BIO invest, Mabwell (Shanghai) Biosci
Enrollment open: A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19 (clinicaltrials.gov) - Feb 26, 2021
P2, N=150, Recruiting,
We propose that structure-activity relationship research might be worthwhile based on the structures of the most effective substances. Not yet recruiting --> Recruiting
- |||||||||| ABP-300 / Abpro, BIO invest, Mabwell (Shanghai) Biosci
Trial completion: A Clinical Study to Evaluate MW33 Injection (clinicaltrials.gov) - Feb 25, 2021
P1, N=42, Completed,
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Deletion of CDR1 reveals redox regulation of pleiotropic drug resistance in Candida glabrata. (Pubmed Central) - Nov 19, 2020
To evaluate the relevance of this redox pathway, we studied the activation of PDR in the yeast Candida glabrata, which we treated with a mitochondrially targeted antioxidant plastoquinonyl-decyl-triphenylphosphonium and dodecyltriphenylphosphonium (CTPP) as a control...It appears that disruption of the PDR1/CDR1 regulatory circuit makes auxiliary PDR regulation mechanisms crucial. Our data suggest that redox regulation of PDR is dispensable in wild-type cells because of redundancy in the activation pathways, but is manifested upon deletion of CDR1.
- |||||||||| ABP-300 / Abpro, BIO invest, Mabwell (Shanghai) Biosci
Enrollment closed, Enrollment change: A Clinical Study to Evaluate MW33 Injection (clinicaltrials.gov) - Sep 2, 2020
P1, N=42, Active, not recruiting,
Our data suggest that redox regulation of PDR is dispensable in wild-type cells because of redundancy in the activation pathways, but is manifested upon deletion of CDR1. Recruiting --> Active, not recruiting | N=32 --> 42
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Preclinical, Journal: SkQ1 Suppresses the p38 MAPK Signaling Pathway Involved in Alzheimer's Disease-Like Pathology in OXYS Rats. (Pubmed Central) - Aug 1, 2020
Earlier, we have shown that mitochondria-targeted antioxidant plastoquinonyl-decyltriphenylphosphonium (SkQ1) at nanomolar concentrations can prevent, slow down, or partially alleviate AD-like pathology in accelerated-senescence OXYS rats...Transcriptome analysis, western blotting, and immunofluorescent staining revealed that SkQ1 suppresses p38 MAPKsp activity in the hippocampus at the level of expression of genes involved in the p38 MAPKsp and reduces the phosphorylation of intermediate kinases (p38 MAPK and MK2) and a downstream protein (αB-crystallin). Thus, the anti-AD effects of SkQ1 are associated with improvement in the functioning of relevant signaling pathways and intracellular processes, thus making it a promising therapeutic agent for human AD.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Journal: Cationic penetrating antioxidants switch off Mn cluster of photosystem II in situ. (Pubmed Central) - Apr 10, 2020
For the first time, we describe a dramatic quenching effect of (10-(6-plastoquinonyl)decyl triphenylphosphonium (SkQ1) on chlorophyll fluorescence, apparently mediated by redox interaction of SkQ1 with Mn cluster in Photosystem II (PSII) of chlorophyte microalga Chlorella vulgaris and disabling the oxygen-evolving complex (OEC)...This effect of the Skulachev ions might help to develop in vivo models of photosynthetic cells with impaired OEC function but essentially intact otherwise. The observed phenomenon suggests that SkQ1 can be applied to study stress-induced damages to OEC in photosynthetic organisms.
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Trial completion: VISTA-1: Study of SkQ1 as Treatment for Dry-eye Syndrome (clinicaltrials.gov) - Nov 20, 2019
P3, N=451, Completed,
The observed phenomenon suggests that SkQ1 can be applied to study stress-induced damages to OEC in photosynthetic organisms. Active, not recruiting --> Completed
- |||||||||| Visomitin (plastoquinonyl decyl triphenylphosphonium) / Mitotech, BIO invest
Enrollment closed: VISTA-1: Study of SkQ1 as Treatment for Dry-eye Syndrome (clinicaltrials.gov) - Jan 4, 2019
P3, N=451, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|
